MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (“GSK”, LSE/NYSE: GSK) to evaluate ivonescimab, a novel, ...
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 11 Best Short Squeeze Stocks to Buy Now. Following mixed results in the clinical trial of Ivonescimab, the company entered a new clinical ...
Multiple Solid Tumor Settings to Be Pursued with Clinical Trials Expected to Start in Mid-2026 MIAMI--(BUSINESS WIRE)-- Summit Therapeutics Inc. (SMMT) today announced it has entered into a clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results